Back to Top

Pharma/BioTech Update: Fidelity and REGENX form Gene Therapy Company

November 1st, 2013; posted by: webleed staff

Fidelity Biosciences, a division of Fidelity Investments that invests venture capital in private pharmaceutical and medical/healthcare technology companies, has inked a deal with REGENX Biosciences to form “Dimension Therapeutics”.

Dimension will focus on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for AAV (Adeno-Associated Virus) therapeutics.

Ken Mills, president and chief executive officer of REGENX told BUSINESS WIRE, “We are pleased to work with Fidelity to establish a new best-in-class company in AAV gene therapy that has the opportunity to invest in the focused development of multiple important rare diseases, including hemophilia.”

Comment Here

Your email address will not be published.


Translate »